2015
Nephrogenic Systemic Fibrosis
LaChance A, Abu-Alfa A, Cowper S. Nephrogenic Systemic Fibrosis. 2015, 119-136. DOI: 10.1007/978-1-4939-2395-3_12.ChaptersNephrogenic systemic fibrosisMagnetic resonance angiographySystemic fibrosisNon-renal patientsOff-label useDiverse medical specialtiesMedication toxicityRenal diseasePathological featuresRenal populationRare conditionUnsuspected conditionsLong-term effectsNew toxicitiesGadolinium retentionResonance angiographyDisease causesTreatment climateNovel diseaseMedical specialtiesFibrosisDiseasePhysiciansPharmaceutical companiesToxicity
2013
Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report
Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE, Abu-Alfa AK, Miller FH, Godinez-Puig V, Dharnidharka VR, West DP. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology 2013, 44: 173-180. PMID: 24057195, PMCID: PMC3946726, DOI: 10.1007/s00247-013-2795-x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisSystemic fibrosisGadolinium-based contrast agentsDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemEvent Reporting SystemRenal functionPediatric casesResearch RegistryContrast agentsFibrosisDuplicate reportingU.S. FoodSystematic searchReported numberRegistryChildrenReporting systemFAERSExposureReportAgentsMethodsWeCases
2012
Nephrogenic systemic fibrosis: concepts and perspectives
de Souza Machado Igreja A, de Carvalho Mesquita K, Cowper SE, Costa IM. Nephrogenic systemic fibrosis: concepts and perspectives. Anais Brasileiros De Dermatologia 2012, 87: 597-607. PMID: 22892775, DOI: 10.1590/s0365-05962012000400013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisGadolinium-based contrast agentsSystemic fibrosisNephrogenic systemic fibrosis casesCareful clinicopathological correlationEffective preventive methodsMagnetic resonance imagingContrast agentsRenal impairmentRenal functionClinicopathological correlationSkin changesProgressive conditionFibrosis casesVisceral organsKidney disordersResonance imagingPreventive methodsPatientsFibrosisDiseaseExposureAgentsRemissionNephrologists
2010
Nephrogenic systemic fibrosis
Braverman IM, Cowper S. Nephrogenic systemic fibrosis. F1000 Medicine Reports 2010, 2: 84. PMID: 21283650, PMCID: PMC3026615, DOI: 10.3410/m2-84.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRenal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature
Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.Peer-Reviewed Case Reports and Technical NotesConceptsNephrogenic systemic fibrosisRenal transplantationSystemic fibrosisSymptoms of NSFEarly renal transplantationUnderwent renal transplantationRare fibrosing disorderStandard therapy existsRenal functionFibrosing disorderRenal diseaseCase reportTherapy existsPatient's lesionTherapeutic modalitiesTransplantationPatientsLesionsFibrosisPhotopheresisPlasmapheresisImatinibSymptomsCareful considerationDisease
2008
NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment
Knopp EA, Cowper SE. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment. Seminars In Dialysis 2008, 21: 123-128. PMID: 18226008, DOI: 10.1111/j.1525-139x.2007.00399.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsEarly recognitionSystemic fibrosisAcute kidney diseaseSignificant risk factorsInvolved extremityRenal dysfunctionRenal insufficiencyExtracorporeal photopheresisRenal functionMedical therapyMuscle weaknessKidney diseaseRisk factorsDistressing diseaseEarly treatmentPhysical therapyEffective treatmentEarly symptomsEarly signsPatientsBeneficial effectsFibrosisTherapyNephrogenic Systemic Fibrosis: An Overview
Cowper SE. Nephrogenic Systemic Fibrosis: An Overview. Journal Of The American College Of Radiology 2008, 5: 23-28. PMID: 18180005, DOI: 10.1016/j.jacr.2007.08.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2007
Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders
Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis & Rheumatism 2007, 56: 3173-3175. PMID: 17907160, DOI: 10.1002/art.22926.Commentaries, Editorials and LettersNephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor
Moreno‐Romero J, Segura S, Mascaró JM, Cowper SE, Julià M, Poch E, Botey A, Herrero C. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. British Journal Of Dermatology 2007, 157: 783-787. PMID: 17627792, DOI: 10.1111/j.1365-2133.2007.08067.x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisDevelopment of NSFRenal insufficiency patientsOnset of symptomsNephrogenic fibrosing dermopathyPossible aetiological factorsMagnetic resonance angiographyRenal diseaseCase seriesAetiological factorsSystemic fibrosisResonance angiographyFibrotic conditionsPatientsParamagnetic contrast agentHistory of useDiseaseContrast agentsAngiographyFibrosisDermopathyEtiologyGadoliniumSymptoms
2006
Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)
Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion In Rheumatology 2006, 18: 614-617. PMID: 17053507, DOI: 10.1097/01.bor.0000245725.94887.8d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisNephrogenic fibrosing dermopathyRenal insufficiencyClinical awarenessSystemic diseaseClinical spectrumTreatment optionsFibrogenic factorsEffective therapyFatal disorderEnigmatic disorderClinical reportsCardinal featuresFibrosisSpecific causesDisordersPathogenesisFibrocytesFuture studiesCauseRheumatologistsPatientsEtiopathogenesisRegistryEditorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients
DeHoratius DM, Cowper SE. Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients. Seminars In Dialysis 2006, 19: 191-194. PMID: 16689966, DOI: 10.1111/j.1525-139x.2006.00152.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisCases of NSFNephrogenic fibrosing dermopathyScleroderma-like diseaseRenal insufficiencyRenal patientsNSF patientsNephrology professionalsPatientsNephrology literatureSoft tissueTissue remodelingWound repairFibrosisSkinSpecific cellsComorbiditiesDermopathyInsufficiencySymptomsDiseaseThe role of circulating fibrocytes in fibrosis
Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Current Rheumatology Reports 2006, 8: 145-150. PMID: 16569374, DOI: 10.1007/s11926-006-0055-x.Peer-Reviewed Original ResearchConceptsPulmonary fibrosisFunctions of fibrocytesAreas of inflammationSerum amyloid PTissue repair responseFibrocyte traffickingInflammatory cytokinesPeripheral bloodMalignant potentialFibrotic lesionsStromal responseIL-1Skin lesionsPathologic fibrosisNew therapiesAmyloid PHypertrophic scarsTissue damageMatrix metalloproteinasesFibrosisRemodeling responseTumor invasionFibrocytesContractile myofibroblastsExperimental model
2002
PULMONARY TOXICITY OF SIMULATED LUNAR AND MARTIAN DUSTS IN MICE: I. HISTOPATHOLOGY 7 AND 90 DAYS AFTER INTRATRACHEAL INSTILLATION
Lam CW, James JT, McCluskey R, Cowper S, Balis J, Muro-Cacho C. PULMONARY TOXICITY OF SIMULATED LUNAR AND MARTIAN DUSTS IN MICE: I. HISTOPATHOLOGY 7 AND 90 DAYS AFTER INTRATRACHEAL INSTILLATION. Inhalation Toxicology 2002, 14: 901-916. PMID: 12396402, DOI: 10.1080/08958370290084683.Peer-Reviewed Original ResearchConceptsParticle-laden macrophagesPeribronchiolar inflammationLung lesionsPulmonary toxicityChronic pulmonary inflammationChronic inflammatory lesionsEvidence of inflammationAcute inflammatory responseNumber of macrophagesFocal alveolitisLung injurySeptal thickeningPulmonary inflammationInflammatory lesionsMild fibrosisExamination 7Chronic mildInflammatory responseAlveolitisFibrosisInflammationLungOverall severityMSS groupMice